Gentian Diagnostics ASA

Legal Proceedings Report • Dec 5, 2022

Patent granted for NT-proBNP in the U.S.

Patent granted for NT-proBNP in the U.S.

Moss, 5 December 2022

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, is pleased to announce that it has been granted a patent in the U.S. for its product candidate NT-proBNP.

NT-proBNP is a non-invasive biomarker for the diagnosis of congestive heart failure (CHF). An aging population and lifestyle choices increase the cost burden in healthcare systems and thereby drive demand for NT-proBNP testing.

Gentian’s assay, which is currently under development, aims to be the first turbidimetric IVD test for NT-proBNP supporting improved laboratory throughput and productivity. Additionally, Gentian aims to contribute to easier standardisation of test results.

“The issued patent is an important milestone towards the development of NT-proBNP as it de-risks the product’s commercial potential. We remain optimistic that we can overcome the remaining challenges in product development,” commented Hilja Ibert, CEO of Gentian Diagnostics.

In its Q3 2022 report, Gentian gave an update on the progress made on NT-proBNP currently in the optimisation phase. A working prototype was established in the quarter and additional testing is ongoing. Further, the establishment of the reference method at the first trial site has been accomplished supporting the process of calibrating the immunoassay towards commercially available products.

The patent for NT-proBNP is issued by the U.S. Patent and Trademark Office.

For further information, please contact:

Hilja Ibert, CEO

hilja.ibert@gentian.no

+47 919 05 242

Njaal Kind, CFO and COO

njaal.kind@gentian.no

+47 919 06 525

About Gentian Diagnostics

Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lie within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.